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Abstract
Background: The hereditary hemochromatosis gene HFE plays a pivotal role in iron homeostasis.
The association between cancer and HFE hetero- or homozygosity has previously been shown
including hepatocellular and nonhepatocellular malignancies. This study was performed to compare
frequencies of HFE C282Y and H63D variants in Turkish women with breast cancer and healthy
controls.
Methods: Archived DNA samples of Hacettepe University Oncology Institute were used in this
study. The HFE gene was investigated by PCR-RFLP.
Results: All subjects studied were free from C282Y mutation. Thirty-nine patients had H63D
mutation and were all heterozygous. H63D allele frequency was 22.2% (39/176) in the breast
cancer patients, and 14% (28/200) in the healthy volunteers. Statistical analysis of cases with HFE
H63D phenotype showed significant difference between breast cancer and healthy volunteers (P =
0.02).
Conclusion: Our results suggest that HFE H63D mutation frequencies were increased in the
breast cancer patients in comparison to those in the general population. Also, odds ratios (odds
ratio = 2.05) computed in this study suggest that H63D has a positive association with breast
cancer.
Background
The hereditary hemochromatosis gene HFE (6p21.3) 4
Mb telomeric to the HLA-A locus, and its product has a
structure similar to MHC class I molecules [1]. It has a crit-
ical role in iron homeostasis. The total number of HFE
variants detected to date is at least 37, of which 19 are mis-
sense [2]. Two mutations, C282Y (the substitution of tyro-
sine for cysteine at position 282) and H63D (the
substitution of aspartate for histidine at position 63), are
particularly frequent among patients with hereditary
hemochromatosis [1] that is characterized by hepatic
fibrosis and cirrhosis, diabetes mellitus, skin pigmenta-
tion, hypogonadism, arthropathy and cardiomyopathy as
a result of excessive iron absorption from the gut and sub-
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sequent accumulation of iron in organs. HFE protein
forms a stable complex with transferrin receptor (TFR),
thereby reducing its affinity for transferrin (TF) by approx-
imately ten fold [3]. TF is the major iron transport protein
in blood and TFR facilitates the uptake of ironbound
transferrin. C282Y mutation prevents the association of
the mutant HFE protein with TFR because of the lack of
cell surface expression [4]. As a result, increased affinity of
the uncomplexed TFR for TF causes higher iron absorp-
tion. The significance of the H63D mutation on the HFE
gene was at first controversial [1,3]. Subsequent studies
suggested a functional role for H63D mutation [3,5,6].
The H63D variant of the HFE protein does reach the cell
surface and forms a stable complex with TFR but fails to
control high TFR affinity for TF [7].
HFE mutation frequencies show marked geographical dif-
ferences throughout the world. Most Caucasian patients
of Northwestern European ancestry with hereditary
hemochromatosis are homozygous for C282Y [8,9].
Compound heterozygotes for the C282Y and H63D
mutations expressing hemochromatosis are also
observed, but with less penetrance than C282Y homozy-
gotes [6,8]. Besides hepatocellular carcinoma [10,11]
common malignancies, including hematological [12-14],
colorectal cancer [15-17], and breast cancer [15,18] show
risk associations with C282Y. However, there are contra-
dictious studies showing no association between the HFE
mutations and cancer risk [19-22].
One possible mechanism for the association might be the
load of reactive free iron molecules which may cause DNA
damage [23,24], which may suppress the host defense
cells and induce proliferation [25,26], and which may
convert nitric oxide from a proapoptotic to an antiapop-
totic molecule [27].
The current report outlines our analysis of C282Y and
H63D mutations in Turkish breast cancer patients and
control subjects from the same geographical area.
Methods
Patients and Controls
In this study, we used 88 archived DNA samples, which
had been isolated from blood samples of patients with
breast cancer diagnosed at Hacettepe University Oncology
Institute Department of Medical Oncology in Turkey over
the last ten years. The mean age at diagnosis for the breast
cancer patients was 41 yr (range, 21–75). The population
controls consisted of 100 DNA samples from voluntary
and healthy women who lived in Ankara, located at cen-
tral Turkey. The mean age of the controls was 33 yr (range,
21–70). This study has been approved by the Hacettepe
University Ethics Committee.
Determination of C282Y mutation of the HFE gene by  restriction enzyme analysis Figure 2
Determination of C282Y mutation of the HFE gene 
by restriction enzyme analysis. Neither homozygote nor 
heterozygote C282Y mutations were found in patients or in 
healthy controls.
Determination of H63D mutation of the HFE gene by restric- tion enzyme analysis Figure 1
Determination of H63D mutation of the HFE gene by 
restriction enzyme analysis. Molecular weight marker 
(MW) sizes are shown on the first lane.BMC Cancer 2006, 6:37 http://www.biomedcentral.com/1471-2407/6/37
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PCR-RFLP
PCR amplification and electrophoresis were performed by
using the standard procedures described previously
[1,28]. The following general HFE primers were used at
annealing temperature of 58°C and 57.4°C for analysis of
C282Y and H63D mutations:
C282Y-Forward; 5'-TGGCAAGGGTAAACAGATCC-3',
C282Y-Reverse; 5'-CTCAGGCACTCCTCTCAACC-3',
H63D-Forward; 5'-ACATGGTTAAGGCCTGTTGC-3',
H63D-Reverse; 5'-GCCACATCTGGCTTGAAATT-3'.
The amplified fragments were digested with RsaI for the
C282Y and BclI for the H63D mutations. Upon digestion
with RsaI, the 387 bp PCR product of C282Y region shows
two fragments of 247 bp and 140 bp in normal DNA and
two additional fragments of 111 bp and 29 bp in mutant
DNA. The 294 bp H63D region PCR product digested
with BclI generates fragments of 138 bp, 70 bp in normal
DNA and 208 bp in mutant DNA [28]. PCR digests were
analyzed on 2.5% agarose gels (Figure 1 and 2). The rela-
tive positions of the mutations analyzed in the present
study are given in Table 1.
Statistical analyses
Frequencies of the HFE alleles were calculated by gene
counting. Hardy-Weinberg equilibrium was tested before
proceeding to the analysis. Statistical analysis of mutation
prevalence in case and control groups was performed by
using two-tailed Fisher's exact test. The proportions of
patients with breast cancer and healthy volunteers who
carried at least one mutant allele are presented with 95%
confidence intervals (CIs) and Odds Ratio (OR). Analyses
were performed by using Instat V2.02 (GraphPad Inc
USA) statistical software package. In general group com-
parisons P value < 0.05 was accepted as statistically signif-
icant whereas in subgroup analysis after making
Bonferroni adjustment P  value < 0.0125 value was
accepted as statistically significant.
Results
According to the birth of place thirty-eight percent of the
entire cases was from Central Turkey, twenty-eight percent
was from South and West (Mediterranean region), twenty
percent was from East, and fifteen percent was from North
(Black Sea region). Information about cancer type and
stages were available for 52 patients, and ninety-three per-
cent of them had infiltrative ductal carcinoma and ninety-
four percent of the women had limited-stage (stages I-III),
3 women (6%) had distant metastases at diagnosis.
There was no significant deviation from Hardy-Weinberg
equilibrium in the distribution of genotypes in the con-
trol group. In the control group of 100 women, HFE
H63D allele frequency was 14%, and the frequency of
HFE  H63D-homozygosity was 1%. Overall allele fre-
quency for breast cancer group of 88 women (71 sporadic
and 17 familial), for HFE H63D was 22.2% whereas there
were no HFE H63D-homozygotes in the group. Statistical
analysis of cases with HFE H63D phenotype showed sig-
nificant difference between breast cancer and healthy vol-
unteers (P = 0.02, OR = 2.05, 95% CI = 1.12 to 3.75)
whereas there was no significant difference between either
Table 2: Characteristics of breast cancer patients
Variable HFE genotype
H63D alleleΨ Wt/Wtξ
Mean age at diagnosis in years (range) 42 (32–75) 40 (26–62)
Premenopausal at diagnosis N = 22 N = 35
Familial N = 8 N = 9
Early onset * N = 12 N = 22
Sporadic N = 31 N = 40
Ψ Heterozygous patients for H63D allele.
ξ Wt/Wt, homozygous wild-type.
* Patients diagnosed at younger than 40 years.
Table 1: HFE mutations with nucleotide changes and their positions within HFE
Mutation Nucleotide change Position relative to initiating 
ATG [GenBank: U60319]
Position in HFE
C282Y G → A 5473 Exon 4
H63D C → G 3513 Exon 2BMC Cancer 2006, 6:37 http://www.biomedcentral.com/1471-2407/6/37
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familial breast cancer and healthy volunteers or familial
and sporadic breast cancer groups (Table 3). Subgroup
analysis showed that the difference between the cases and
control groups is based on the sporadic cases (P = 0.0001,
OR = 3.13, 95% CI = 1.65 to 5.94). Information for the
pre- and post-menopausal status was available for only 64
patients. Statistical analysis of cases with HFE  H63D
mutation among these patients showed no significant dif-
ferences between premenopasual and postmenopausal
breast cancer (Table 3). Characteristics of breast cancer
patients with respect to H63D allele are summarized in
Table 2. There were also no statistically significant differ-
ences between breast cancer patients with and without the
H63D allele with respect to age or heredity. All subjects
studied were free from C282Y mutation.
Discussion
As expected from previous population studies [29-31] we
did not find any C282Y mutation among the Turkish
women who participated in this study. The results of this
case-control study showed that H63D was more common
in breast cancer patients. Because endogenous estrogens
are more closely related to postmenopausal breast cancer
and iron might have a role at redox-cycling estrogen
metabolites to produce hydroxyl radicals [32,33], we
compared premenopasual and postmenopausal breast
cancer for the HFE H63D mutation. Since significant iron
loss stops with menopause, an increase in HFE-associated
cancer risk might also be possible. Contrary, there was no
statistically significant difference between these groups (P
= 0.12).
To the best of our knowledge, this is the second study that
shows a significant association between female breast can-
cer and HFE-H63D although a subgroup analysis in a gen-
eral cancer association study also revealed a non-
significantly increased odds ratio for H63D carriers (n =
18, OR = 2.0, P = 0.14) in breast cancer [12]. A recent arti-
cle, making the same comparisons of H63D mutation fre-
quency between Russian women with breast cancer and
controls, found age to be an important confounder of the
association, wherein a positive association of H63D with
breast cancer was only found among women over 57 years
old [34]. Because of the insufficient number of the
women over 45 years old in our study (Control N = 5,
Cases N = 22), the estimation could be made in wide
range which might cause unreliable interpretations.
Therefore, age-specific analysis was not performed in this
study. Another recent study showed no association
between male breast cancer and H63D [35]. Although the
lack of gender difference shown in association between
HFE  genotypes and medical conditions related to iron
overload other than cancer [36], this variability in women
with H63D mutations with respect to cancer risk could be
the influence of potential modifier factors for breast can-
cer. The only other cancer association with H63D is with
malignant gliomas [37]. If replicated elsewhere, further
studies can be designed to distinguish between mechanis-
tic possibilities. Our study had some limitations. We were
unable to study the effect of H63D on serum iron param-
eters or gene and environment interactions, as we did not
have stored serum samples from patients nor dietary or
medication (oral contraceptives, etc) history. Ideally, a
sample larger than ours should be studied in a genetic
association study to rule out the chance factor. Not only is
the study small, but when a small number of multiple
comparisons are made, the power of the study is further
diminished. When Bonferroni correction were made the
comparison between the cases and controls in this study
was no longer significant (p = 0.02 vs. a = 0.0125).
We compared the data on H63D frequencies from other
population studies in Turkey. Our control frequency from
age-matched females is in general agreement with other
Table 3: Statistical analysis of cases with H63D mutation. Analysis between Total breast cancer patients and Healthy controls, 
Sporadic breast cancer patients and Healthy controls, Familial breast cancer patients and Healthy controls, Sporadic breast cancer 
and Familial breast cancer patients, Premenopausal and Postmenopausal breast cancer patients are shown. One healthy volunteer 
was homozygous for the mutation; all other subjects listed here were heterozygous. All the subjects studied were free from C282Y 
mutation.
Cases with H63D mutation P value
(two-sided)
Odds ratio 
(OR)
%95 Confidence Interval-CI-
(using the approximation of Woolf)
Total breast cancer patients: Healthy 
controls
39/88: 28/100 0.02 2.05 1.12 to 3.75
Sporadic breast cancer patients: Healthy 
controls
31/71: 28/100 0.05 2 1.05 to 3.78
Familial breast cancer patients: Healthy 
controls
8/17: 28/100 0.15 2.29 0.80 to 6.52
Sporadic breast cancer patients: Familial 
breast cancer patients
31/71: 8/17 1 1.15 0.4 to 3.32
Premenopausal breast cancer patients: 
Post menopausal breast cancer patients
22/57: 5/7 0.12 0.25 0.04 to 1.41BMC Cancer 2006, 6:37 http://www.biomedcentral.com/1471-2407/6/37
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results which are 13.6%, 11.6% respectively [29,30]. The
only exception is the study by Simsek et al., which
reported a higher H63D mutation frequency (24.9%)
from predominantly male blood donors [31]. A larger
control group consisting of truly population-based
females would have yielded a more robust estimate of the
frequency if we had had the resources to achieve that.
The role of H63D in iron homeostasis is well established.
Although an animal study unambiguously showed an
effect of H63D mutation on hemochromatosis develop-
ment [38], a human twin study established the influence
of H63D on transferrin saturation levels [39]. Significant
increases in both transferrin saturation and serum ferritin
levels in H63D heterozygotes versus HFE wild type con-
trols have also been demonstrated in large population
studies [40-42]. HFE  H63D mutation is very variable
worldwide. The carrier frequency of the H63D mutation is
21.6% in Europe, 5.4% in Africa/Middle-East, 2.8% Asia
and 22.8% in America [9]. One possibility is that H63D
association with breast cancer might have been a selection
of a specific subgroup among Turkish population. Turkey
has a very heterogeneous population whose ancestries are
from Anatolia (east Mediterranean region), Middle East
and Central Asia. Related or unrelated susceptibility gene
mutations, especially the ones which show ethnic
dependence may both arise at higher frequencies in a spe-
cific subgroup of the mix-population. However, being a
reference center Hacettepe Oncology Institute has the
potential to comprise patients from different regions of
Turkey and therefore, it is less likely that a specific sub-
group of the population has been selected for this study.
Despite a large physical distance, the genetic distance
between HFE and the telomeric end of the HLA complex
is less than 1 cM. This results in linkage disequilibrium
between H63D and HLA-A29 [43,44]. One alternative
explanation is therefore confounding by locus, e.g., an
HLA association may have appeared as H63D association
in our study due to linkage disequilibrium. HLA loci have
been studied in breast cancer and several associations
have been reported but most importantly a recent large
family study mapped a breast cancer susceptibility locus
towards the telomeric end of the HLA complex [45]. The
region between HFE and the HLA complex has another
feature that may be relevant in the mechanism of an asso-
ciation with H63D. A significant correlation with CD8+ T-
cell numbers, but not with CD4+ T-cell numbers, in sub-
jects carrying both HLA-A29 and H63D or both HLA-
A*01 and H63D mutation has been reported [44,46].
Thus, the H63D association may be a reflection of an
immune response gene association in the region between
HFE and HLA. Further large studies on HFE association
with breast cancer susceptibility in populations lacking
the C282Y mutation may need to include markers from
HLA loci, loci between the HLA complex and HFE and
other variants of the HFE  gene for more meaningful
results than our preliminary study has shown.
Conclusion
We did not find any C282Y mutation among the Turkish
women who participated in this study. The results of this
case-control study show that H63D has a positive associa-
tion with breast cancer. However, when a small number of
multiple comparisons are made, the power of the study is
diminished. Ideally, a sample larger than ours should be
studied in a genetic association study to rule out the
chance factor.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
AGO designed the study, carried out the molecular genetic
(PCR-RFLP) studies, performed the statistical analysis and
drafted the manuscript. SAB participated in the PCR-RFLP
studies. ENG is the medical oncologist who diagnosed
breast cancer patients and gave the related information.
DG provided DNA samples of the patients and control
group and helped to draft the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
This work was supported in part by Kirikkale University Research Found 
(KÜ AF 02/08.01.04) and Eczacibasi Scientific Research and Award Found. 
We thank the cancer patients and healthy volunteers who made this analy-
sis possible. We also thank Professor M. Oguz Guc and Handan Camde-
viren-Ankarali for reviewing the statistical analysis.
References
1. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A,
Dormishian F, Domingo R Jr, Ellis MC, Fullan A, Hinton LM, Jones NL,
Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA,
McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang
E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ,
Drayna DT, Risch NJ, Bacon BR, Wolff RK: A novel MHC class I-
like gene is mutated in patients with hereditary haemochro-
matosis.  Nat Genet 1996, 13:399-408.
2. Beutler L, Beutler E: Hematologically important mutations:
iron storage diseases.  Blood Cells Mol Dis 2004, 33:40-44.
3. Feder JN, Penny DM, Irrinki A, Lee VK, Lebron JA, Watson N, Tsuch-
ihashi Z, Sigal E, Bjorkman PJ, Schatzman RC: The hemochromato-
sis gene product complexes with the transferrin receptor
and lowers its affinity for ligand binding.  Proc Natl Acad Sci USA
1998, 95:1472-1477.
4. Feder JN, Tsuchihashi Z, Irrinki A, Lee VK, Mapa FA, Morikang E,
Prass CE, Starnes SM, Wolff RK, Parkkila S, Sly WS, Schatzman RC:
The hemochromatosis founder mutation in HLA-H disrupts
b2-microglobulin interaction and cell surface expression.  J
Biol Chem 1997, 272:14025-14028.
5. Beutler E: The significance of the 187G (H63D) mutation in
hemochromatosis.  Am J Hum Genet 1997, 61:762-764.
6. Fairbanks VF, Brandhagen DJ, Thibodeau SN, Snow K, Wollan PC:
H63D is an haemochromatosis associated allele.  Gut 1998,
43:441-442.
7. Waheed A, Parkkila S, Zhou XY, Tomatsu S, Tsuchihashi Z, Feder JN,
Schatzman RC, Britton RS, Bacon BR, Sly WS: Hereditary hemo-
chromatosis: effects of C282Y and H63D mutations on asso-BMC Cancer 2006, 6:37 http://www.biomedcentral.com/1471-2407/6/37
Page 6 of 7
(page number not for citation purposes)
ciation with beta2-microglobulin, intracellular processing,
and cell surface expression of the HFE protein in COS-7
cells.  Proc Natl Acad Sci USA 1997, 94:12384-12389.
8. Beutler E, Gelbart T, West C, Lee P, Adams M, Blackstone R, Pockros
P, Kosty M, Venditti CP, Phatak PD, Seese NK, Chorney KA, Ten
Elshof AE, Gerhard GS, Chorney M: Mutation analysis in heredi-
tary hemochromatosis.  Blood Cells Mol Dis 1996, 22:187-194.
9. Hanson EH, Imperatore G, Burke W: HFE gene and Hereditary
Hemochromatosis: a HuGE review. Human Genome Epide-
miology.  Am J Epidemiol 2001, 154:193-206.
10. Hellerbrand C, Poppl A, Hartmann A, Scholmerich J, Lock G: HFE
C282Y heterozygosity in hepatocellular carcinoma: evi-
dence for an increased prevalence.  Clin Gastroenterol Hepatol
2003, 1:279-284.
11. Cauza E, Peck-Radosavljevic M, Ulrich-Pur H, Datz C, Gschwantler M,
Schoniger-Hekele M, Hackl F, Polli C, Rasoul-Rockenschaub S, Muller
C, Wrba F, Gangl A, Ferenci P: Mutations of the HFE gene in
patients with hepatocellular carcinoma.  Am J Gastroenterol
2003, 98:442-447.
12. Barton JC, Bertoli LF, Acton RT: HFE C282Y and H63D in adults
with malignancies in a community medical oncology prac-
tice.  BMC Cancer 2004, 4:6.
13. Dorak MT, Burnett AK, Worwood M, Sproul AM, Gibson BE: The
C282Y mutation of HFE is another male-specific risk factor
for childhood acute lymphoblastic leukemia.  Blood 1999,
94:3957-3958.
14. Dorak MT, Burnett AK, Worwood M: HFE gene mutations in
susceptibility to childhood leukemia: HuGE review.  Genet
Med 2005, 7:159-167.
15. Beckman LE, Van Landeghem GF, Sikström C, Wahlin A, Markevarn
B, Hallmans G, Lenner P, Athlin L, Stenling R, Beckman L: Interac-
tion between haemochromatosis and transferrin receptor
genes in different neoplastic disorders.  Carcinogenesis 1999,
20:1231-1233.
16. Altes A, Gimferrer E, Capella G, Barcelo MJ, Baiget M: Colorectal
cancer and HFE gene mutations.  Haematologica 1999,
84:479-480.
17. Robinson JP, Johnson VL, Rogers PA, Houlston RS, Maher ER, Bishop
DT, Evans DG, Thomas HJ, Tomlinson IP, Silver AR: Evidence for
association between compound heterozygosity for germ line
mutations in the hemochromatosis (HFE) gene and
increased risk colorectal cancer.  Cancer Epidemiol Biomarkers
Prev 2005, 14:1460-1463.
18. Kallianpur AR, Hall LD, Yadav M, Christman BW, Dittus RS, Haines
JL, Parl FF, Summar ML: Increased Prevalence of the HFE C282Y
Hemochromatosis Allele in Women with Breast Cancer.
Cancer Epidemiol Biomarkers Prev 2004, 13:205-212.
19. Hannuksela J, Savolainen ER, Koistinen P, Parkkila S: Prevalence of
HFE genotypes, C282Y and H63D, in patients with hemato-
logic disorders.  Haematologica 2002, 87:131-135.
20. van der ADL, van der Hel O, Roest M, van der Shouw YT, van Gils
CH, Marx JJ, van Noord PA, Peeters PH: Heterozygosity for the
Cys282Tyr mutation in the HFE gene and the risk of color-
ectal cancer (Netherlands).  Cancer Causes Control 2003,
14:541-545.
21. Dorak MT, Burnett AK, Worwood M: Hemochromatosis gene in
leukemia and lymphoma.  Leuk Lymphoma 2002, 43:467-477.
22. Abraham BK, Justenhoven C, Pesch B, Harth V, Weirich G, Baisch C,
Rabstein S, Ko YD, Bruning T, Fischer HP, Haas S, Brod S, Oberkanins
C ,  H a m a n n  U ,  B r a u c h  H ,  G E N I C A  N e t w o r k :  Investigation of
genetic variants of genes of the hemochromatosis pathway
and their role in breast cancer.  Cancer Epidemiol Biomarkers Prev
2005, 14:1102-1107.
23. Nunoshiba T, Obata F, Boss AC, Oikawa S, Mori T, Kawanishi S,
Yamamoto K: Role of iron and superoxide for generation of
hydroxyl radical, oxidative DNA lesions, and mutagenesis in
Escherichia coli.  J Biol Chem 1999, 274:34832-34837.
24. Sarkar B: Metal replacement in DNA-binding zinc finger pro-
teins and its relevance to mutagenicity and carcinogenicity
through free radical generation.  Nutrition 1995, 11:646-649.
25. de Sousa M: Immune cell functions in iron overload.  Clin Exp
Immunol 1989, 75:1-6.
26. Green R, Esparza I, Schreiber R: Iron inhibits the non-specific
tumoricidal activity of macrophages: a possible contributory
mechanism for neoplasia in hemochromatosis.  Ann N Y Acad
Sci 1988, 526:301-309.
27. Bergeron RJ, Streiff RR, Elliot GT: Influence of iron on in vivo pro-
liferation and lethality of L 1210 cells.  J Nutr 1985, 115:369-374.
28. Koeken A, Cobbaert C, Quint W, van Doorn LJ: Genotyping of
hemochromatosis-associated mutations in the HFE gene by
PCR-RFLP and a novel reverse hybridization method.  Clin
Chem Lab Med 2002, 40(2):122-125.
29. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ: Glo-
bal prevalence of putative haemochromatosis mutations.  J
Med Genet 1997, 34:275-278.
30. Bozkaya H, Bektas M, Metin O, Erkan O, Ibrahimoglu D, Dalva K,
Akbiyik F, Gurel S, Bozdayi AM, Akay C, Yurdaydin C, Aslan O, Uzu-
nalimoglu O: Screening for hemochromatosis in Turkey.  Dig
Dis Sci 2004, 49:444-449.
31. Simsek H, Sumer H, Yilmaz E, Balaban YH, Ozcebe O, Hascelik G,
Buyukask Y, Tatar G: Frequency of HFE mutations among
Turkish blood donors according to transferrin saturation:
genotype screening for hereditary hemochromatosis among
voluntary blood donors in Turkey.  J Clin Gastroenterol 2004,
38:671-675.
32. Liehr JG, Jones JS.: Role of iron in estrogen-induced cancer.  Curr
Med Chem 2001, 8:839-849.
33. Malins DC, Polissar NL, Gunselman SJ: Progression of human
breast cancer to the metastatic state is linked to hydroxyl
radical-induced DNA damage.  Proc Natl Acad Sci USA 1996,
93:2557-2563.
34. Kondrashova TV, Neriishi K, Ban S, Ivanova TI, Krikunova LI, Shen-
tereva NI, Smirnova IA, Zharikova IA, Konova MV, Taira S, Tsyb AF:
Frequency of hemochromatosis gene (HFE) mutations in
Russian healthy women and patients with estrogen-depend-
ent cancers.  Biochim Biophys Acta 2005, 1762(1):59-65.
35. Syrjakoski KFH, Ikonen T, Kuukasjarvi T, Autio V, Matikainen MP,
Tammela TLJ, Koivisto PA, Schleutker J: Hemochromatosis gene
mutations among Finnish male breast and prostate cancer
patients.  Int J Cancer 2006, 118:518-520.
36. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH,
McLaren GD, Dawkins FW, Acton RT, Harris EL, Gordeuk VR, Leien-
decker-Foster C, Speechley M, Snively BM, Holup JL, Thomson E,
Sholinsky P: Hemochromatosis and iron-overload screening in
a racially diverse population.  N Engl J Med 2005, 352:1769-1778.
37. Martinez di Montemuros F, Tavazzi D, Salsano E, Piepoli T, Pollo B,
Fiorelli G, Finocchiaro G: High frequency of the H63D mutation
of the hemochromatosis gene (HFE) in malignant gliomas.
Neurology 2001, 57:1342.
38. Tomatsu S, Orii KO, Fleming RE, Holden CC, Waheed A, Britton RS,
Gutierrez MA, Velez-Castrillon S, Bacon BR, Sly WS: Contribution
of the H63D mutation in HFE to murine hereditary hemo-
chromatosis.  Proc Natl Acad Sci USA 2003, 100:15788-15793.
39. Whitfield JB, Cullen LM, Jazwinska EC, Powell LW, Heath AC, Zhu G,
Duffy DL, Martin NG: Effects of HFE C282Y and H63D poly-
morphisms and polygenic background on iron stores in a
large community sample of twins.  Am J Hum Genet 2000,
66:1246-1258.
40. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T: Penetrance of
845G--> A (C282Y) HFE hereditary haemochromatosis
mutation in the USA.  Lancet 2002, 359:211-218.
41. Jackson H, Carter K, Darke C, Guttridge MG, Ravine D, Hutton RD,
Napier JA, Worwood M: HFE mutations, iron deficiency and
overload in 10,500 blood donors.  Br J Haematol 2001,
114:474-484.
42. Burke W, Imperatore G, McDonnell SM, Baron RC, Khoury MJ: Con-
tribution of different HFE genotypes to iron overload dis-
ease: a pooled analysis.  Genet Med 2000, 2:271-277.
43. Porto G, Alves H, Rodrigues P, Cabeda JM, Portal C, Ruivo A, Justica
B, Wolff R, de Sousa M: Major histocompatibility complex class
I associations in iron overload: evidence for a new link
between the HFE H63D mutation, HLA-A29, and non-classi-
cal forms of hemochromatosis.  Immunogenetics 1998,
47:404-410.
44. Cardoso CS, Alves H, Mascarenhas M, Goncalves R, Oliveira P, Rod-
rigues P, Cruz E, de Sousa M, Porto G: Co-selection of the H63D
mutation and the HLA-29 allele: a new paradigm of linkage
disequilibrium?  Immunogenetics 2002, 53:1002-1008.
45. de Jong M, Nolte IM, de Vries EGE, Schaapveld M, Kleibeuker JH,
Oosterom E, Oosterwijk JC, van der Hout AH, van der Steege G,
Bruinenberg M, Boezen HM, Te Meerman GJ, van der Graaf WT: ThePublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2006, 6:37 http://www.biomedcentral.com/1471-2407/6/37
Page 7 of 7
(page number not for citation purposes)
HLA class III subregion is responsible for an increased breast
cancer risk.  Hum Mol Gen 2003, 12:2311-2319.
46. Cruz E, Vieira J, Gonçalves R, Alves H, Almeida S, Rodrigues P, Lac-
erda R, Porto G: Involvement of the Major Histocompatibility
Complex region in the genetic regulation of circulating
CD8+ T-cell numbers in humans.  Tissue Antigens 2004, 64:25-34.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/6/37/prepub